|1.||Dugall, M: 21 articles (02/2015 - 10/2004)|
|2.||Belcaro, G: 21 articles (02/2015 - 10/2004)|
|3.||Ippolito, E: 18 articles (02/2015 - 10/2004)|
|4.||Cesarone, M R: 18 articles (03/2014 - 10/2004)|
|5.||Rohdewald, P: 16 articles (09/2010 - 01/2001)|
|6.||Hosoi, M: 15 articles (02/2015 - 11/2005)|
|7.||Cacchio, M: 15 articles (06/2014 - 07/2005)|
|8.||Ricci, A: 14 articles (02/2014 - 10/2004)|
|9.||Ledda, A: 14 articles (02/2014 - 11/2005)|
|10.||Di Renzo, A: 13 articles (09/2010 - 10/2004)|
09/01/2010 - "The aim of this study was to evaluate the clinical efficacy of standardized French maritime pine bark extract Pycnogenol in patients with severe chronic venous insufficiency (CVI). "
10/01/2006 - "In conclusion, this study confirms the fast clinical efficacy of Pycnogenol in patients with chronic venous insufficiency and venous microangiopathy. "
10/01/2006 - "The aim of this study was to investigate the clinical efficacy of oral Pycnogenol (Horphag Research Ltd, UK) in patients with severe chronic venous insufficiency. "
10/01/2000 - "The aim of out study was to investigate the efficacy of Pycnogenol - a French maritime pine bark extract - in the treatment of chronic venous insufficiency (CVI). "
03/01/2014 - "Improvements of venous tone with pycnogenol in chronic venous insufficiency: an ex vivo study on venous segments."
04/01/2006 - "At the end of the study, microcirculatory results indicated: a progressive decrease of skin flux at rest (RF); a significant decrease in capillary filtration (RAS); an improvement in the symptomatic venous score (ASLS); a reduction in edema; a significant improvement (increase) in pO(2) and a decrease in pCO(2) in the Pycnogenol group. "
10/01/2006 - "At 4 and 8 weeks, in all Pycnogenol-treated subjects, microcirculatory and clinical evaluations indicated a progressive decrease in skin flux, indicating an improvement in the level of microangiopathy; a significant decrease in capillary filtration; a significant improvement in the symptomatic score; and a reduction in edema. "
10/01/2000 - "Pycnogenol significantly improved the legs' heaviness and subcutaneous edema; the venous pressure was also significantly reduced by the Pycnogenol treatment, thus adding further clinical evidence to its therapeutic efficacy in patients with CVI. "
11/01/2005 - "Oral Pycnogenol is effective in venous disease and particularly in controlling edema. "
09/01/2008 - "From their previous clinical experience the authors suggest that alleviation of side effects described in this study results from Pycnogenol activities related to endothelial protection, and anti-inflammatory anti-edema activities. "
08/01/2008 - "Following treatment with Pycnogenol patients reported an improvement of WOMAC index (p < 0.05), and a significant alleviation of pain by visual analogue scale (p < 0.04), the placebo had no effect. "
03/01/2006 - "These results indicate the potential of Pycnogenol to reduce pain associated with pregnancy."
03/01/2006 - "Pycnogenol alleviates pain associated with pregnancy."
10/01/2004 - "The number of days with pain was significantly lower (p < 0.01) in the second cycle of treatment with Pycnogenol. "
06/01/2000 - "Pycnogenol treatment induced a significant reduction in subcutaneous edema as well as heaviness and pain in the legs, on both after 30 and 60 days, the evaluation time periods. "
04/01/2008 - "The aim of this double-blind, placebo-controlled study was to evaluate the efficacy of 100 mg Pycnogenol daily (oral capsules) in a 3 month study in patients with osteoarthritis (OA). "
01/01/2008 - "In a previous, double-blind, placebo-controlled study we evaluated the efficacy of a 3-month treatment with Pycnogenol for 156 patients with osteoarthritis of the knee. "
08/01/2008 - "The safe and efficacious use of Pycnogenol (French maritime pine bark extract) in other inflammatory diseases prompted this study of its antiinflammatory effects in patients with osteoarthritis (OA). "
04/01/2008 - "Treatment of osteoarthritis with Pycnogenol. "
01/01/2008 - "In this study, we further investigated the anti-inflammatory and antioxidant activity of Pycnogenol in a subset of the osteoarthritis patients presenting with elevated C-reactive protein (CRP) and plasma-free radicals. "
10/01/2010 - "Pycnogenol is now utilized throughout the world as a nutritional supplement and as a phytochemical remedy for various diseases ranging from chronic inflammation to circulatory dysfunction, including several impaired psycho-physiological functions. "
09/01/2011 - "In addition, several key markers of oxidative stress and inflammation were measured for pycnogenol's beneficial effects. "
09/01/2011 - "We also sought to further delineate the underlying mechanisms elicited by oxidative stress and inflammation and suppressed by pycnogenol. "
02/01/2004 - "Thus, topical Pycnogenol offered significant and dose-dependent protection from SSUV-induced acute inflammation, immunosuppression and carcinogenesis, when applied to the skin after daily irradiation. "
02/01/2004 - "Protection from inflammation, immunosuppression and carcinogenesis induced by UV radiation in mice by topical Pycnogenol."
|10.||Silicon Dioxide (Sand)
|1.||Enteral Nutrition (Feeding, Tube)
|2.||Drug Therapy (Chemotherapy)
|4.||Artificial Respiration (Mechanical Ventilation)